PDE5 inhibitors: looking beyond ED.
Jackson
Graham
G
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002318:Cardiovascular Diseases / Q000188:drug therapy; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases; D014664:Vasodilation / Q000187:drug effects
D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human